At Genetek Lifesciences, we are proud to announce two major developments that strengthen our position as a trusted partner in healthcare innovation.

On one front, we are introducing sterile formulations tailored for clinical trials, ensuring safety, precision, and international compliance to accelerate the development of novel therapies. These formulations are designed to support pharmaceutical companies and research institutions in advancing treatments from concept to commercialization.

Simultaneously, we are expanding our Active Pharmaceutical Ingredient (API) portfolio, offering high-quality contrast media APIs, including:

• Gadopentetate Dimeglumine
• Gadoterate Meglumine
• Gadodiamide
• Gadobutrol
• Ethiodized esters of poppyseed oil

This expansion enables our partners worldwide to access reliable, regulatory-compliant APIs that contribute to safer diagnostics and improved patient care.

Together, these initiatives reflect our commitment to innovation, accessibility, and global collaboration in healthcare.